Literature DB >> 15046104

Successful treatment of long QT syndrome-induced ventricular tachycardia with esmolol.

J Balcells1, M Rodríguez, M Pujol, J Iglesias.   

Abstract

Esmolol is a cardioselective beta-blocker with very rapid onset of action and short half-life due to its metabolism by blood-borne esterases. This unique profile among currently available beta-blockers renders esmolol highly useful in critical care situations. However, published experience with the use of esmolol in critically ill children is scant. The case of a 4-year-old boy with secondary long QT syndrome and ventricular tachycardia successfully treated with esmolol is presented.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15046104     DOI： 10.1007/s00246-003-0620-2

Source DB:  PubMed          Journal:  Pediatr Cardiol        ISSN： 0172-0643            Impact factor:   1.655


  12 in total

Review 1.  Recurrent ventricular tachycardia in hypothyroidism--report of a case and review of the literature.

Authors:  G Nesher; M M Zion
Journal:  Cardiology       Date:  1988       Impact factor: 1.869

2.  Esmolol for the management of pediatric hypertension after cardiac operations.

Authors:  D B Wiest; S S Garner; W E Uber; R M Sade
Journal:  J Thorac Cardiovasc Surg       Date:  1998-04       Impact factor: 5.209

3.  Use of esmolol in the intraoperative management of pheochromocytoma.

Authors:  E Nicholas; C S Deutschman; M Allo; P Rock
Journal:  Anesth Analg       Date:  1988-11       Impact factor: 5.108

4.  Pharmacokinetics of esmolol in children.

Authors:  D B Wiest; D L Trippel; P C Gillette; S S Garner
Journal:  Clin Pharmacol Ther       Date:  1991-06       Impact factor: 6.875

5.  Emergency department management of thyrotoxic crisis with esmolol.

Authors:  D D Brunette; C Rothong
Journal:  Am J Emerg Med       Date:  1991-05       Impact factor: 2.469

Review 6.  Esmolol. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy.

Authors:  P Benfield; E M Sorkin
Journal:  Drugs       Date:  1987-04       Impact factor: 9.546

Review 7.  Esmolol: a titratable short-acting intravenous beta blocker for acute critical care settings.

Authors:  P Turlapaty; A Laddu; V S Murthy; B Singh; R Lee
Journal:  Am Heart J       Date:  1987-10       Impact factor: 4.749

8.  Pharmacodynamics and pharmacokinetics of esmolol, a short-acting beta-blocking agent, in children.

Authors:  B F Cuneo; V R Zales; P C Blahunka; D W Benson
Journal:  Pediatr Cardiol       Date:  1994 Nov-Dec       Impact factor: 1.655

Review 9.  Managing critically ill patients with esmolol. An ultra short-acting beta-adrenergic blocker.

Authors:  R J Gray
Journal:  Chest       Date:  1988-02       Impact factor: 9.410

10.  Autonomic dysfunction and Guillain-Barré syndrome. The use of esmolol in its management.

Authors:  M A Calleja
Journal:  Anaesthesia       Date:  1990-09       Impact factor: 6.955
View more
  3 in total

1.  Long QT syndrome: A therapeutic challenge.

Authors:  Maully Shah; Christopher Carter
Journal:  Ann Pediatr Cardiol       Date:  2008-01

2.  In Vitro Drug Screening Using iPSC-Derived Cardiomyocytes of a Long QT-Syndrome Patient Carrying KCNQ1 & TRPM4 Dual Mutation: An Experimental Personalized Treatment.

Authors:  Feifei Wang; Yafan Han; Wanyue Sang; Lu Wang; Xiaoyan Liang; Liang Wang; Qiang Xing; Yankai Guo; Jianghua Zhang; Ling Zhang; Tuerhong Zukela; Jiasuoer Xiaokereti; Yanmei Lu; Xianhui Zhou; Baopeng Tang; Yaodong Li
Journal:  Cells       Date:  2022-08-11       Impact factor: 7.666

3.  Successful treatment of cardiac electrical storm in dilated cardiomyopathy using esmolol: A case report.

Authors:  L I Li; Yuan-Li Zhou; Xue-Jing Zhang; Hua-Ting Wang
Journal:  Exp Ther Med       Date:  2016-04-20       Impact factor: 2.447
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.